semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Atypical Hemolytic Uremic Syndrome   TTP, (defined as activity <5%) from an historical observation (prior to initiation of plasma therapy) or as tested at the screening visit by the central laboratory 2. Malignancy within 5 years of screening 3. Typical HUS (Shiga toxin +) 4. Known HIV infection 5. Identified drug exposure-related HUS. 6. Infection-related HUS 7. HUS related to bone marrow transplant 8. HUS related to vitamin B12 deficiency 9. Renal function status requiring chronic dialysis 10. Patients with a confirmed diagnosis of sepsis 11. Presence or suspicion of active and untreated systemic bacterial infection that, in the opinion of the Investigator confounds an accurate diagnosis of aHUS or impedes the ability to manage the aHUS disease 12. Pregnancy or lactation 13. Unresolved meningococcal disease 14. Known Systemic Lupus Erythematosus (SLE) or antiphospholipid antibody positivity or syndrome 15. Any medical or psychological condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study 16. Patients who have received previous treatment with eculizumab 17. Patients receiving IVIG within 8 weeks or Rituximab therapy within 12 weeks of screening. 18. Patients receiving other immunosuppressive therapies such as steroids, mTOR inhibitors or tacrolimus are excluded unless: [1] part of an established post-transplant anti-rejection regime, [2] patient has confirmed anti-CFH antibody requiring immunosuppressive therapy, and [3] dose of such medications have been unchanged for at least 4 weeks prior to the screening period or [4] patient is experiencing an acute aHUS relapse immediately after transplant 19. Patients receiving Erythrocyte Stimulating Agents (ESAs) unless already on a stable dose for at least 4 weeks prior to the screening period, or a washout period of at least 2 weeks from the last dose of ESA therapy. 20. Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedures beginning 4 weeks prior to screening and throughout the entire trial. 21. Hypersensitivity to eculizumab, to murine proteins or to one of the excipients
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure Men and women of 18 years old or older history and clinical findings of heart failure for at least three months before screening Patients have to be in New York Heart Association (NYHA) class II, III, or IV and clinically stable Left ventricular ejection fraction <50% GFR ≤ 40 ml/min/1.73m² as calculated the abbreviated MDRD formula  pregnancy as determined by urine test for reproductive-aged females current or past renal replacement therapy current treatment for hyperphosphatemia a history of renal transplantation or CABG Symptoms consistent with Canadian Cardiovascular Society > class 1 angina Inability to comprehend or unwillingness to sign informed consent chronic atrial fibrillation
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 11.0-18.0,  Meningococcal Meningitis Subjects enrolled in V59P13 healthy subjects who have completed the V59P13 study. Naïve subjects healthy subjects aged-matched with subjects who had completed the V59P13 trial.(currently 16-23 years old)  Subjects who had completed the V59P13 study who received any meningococcal vaccine after the V59P13 trial who have had previous confirmed or suspected disease caused by N. meningitidis who have had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis (serogroups A, C, W135, or Y) subjects with any serious, acute or chronic progressive disease. Naïve subjects who previously received any meningococcal vaccine who have had previous confirmed or suspected disease caused by N. meningitidis who have had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis (serogroups A, C, W135, or Y) subjects with any serious, acute or chronic progressive disease
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 14.0-27.0,  Meningococcal Infections Meningitis For subjects aged ≥ 18 years: Informed consent form signed and dated by the subject For subjects aged < 18 years: Informed consent form signed and dated by the subject and the subject's parent/legal guardian Subject (and parent/legal guardian if subject is < 18 years of age) able to attend the scheduled visit and comply with all trial procedures For Group 1: Previously received only one dose of meningococcal vaccine (Menactra®, received in Study MTA04, MTA12, MTA19, or MTA21) For Group 2: Previously received only one dose of meningococcal vaccine (Menomune®, received in Study MTA04) For Group 3: Aged 14 through 27 years and never received any meningococcal vaccine  Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy > 2 weeks Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the investigator Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures Receipt of blood or blood-derived products in the past 3 months that might interfere with the assessment of immune responses Known Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C seropositivity History of invasive meningococcal disease (confirmed either clinically, serologically, or microbiologically) For Groups 1 and 2: Previous vaccination (including booster) against meningococcal disease, with the exception of the Menactra® or Menomune® vaccination received in trial MTA04, MTA12, MTA19, or MTA21 Subjects deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent Received oral or injected antibiotic therapy within the 72 hours prior to the blood draw (temporary criteria)
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 2.0-17.0,  Hemoglobinuria, Paroxysmal Participants between 2 and 17 years of age Diagnosed with PNH Participants with ≥ 5% glycosylphosphatidylinositol-deficient red blood cells or granulocytes as confirmed by flow cytometry Participants must have shown evidence of hemolytic anemia as documented by lactate dehydrogenase greater than the upper limit of normal or at least 1 transfusion in the past 2 years for anemia or anemia related symptoms Written informed consent from a parent/guardian Negative pregnancy test for females of child bearing potential at screening Sexually active females must have documented a reliable and medically approved method of contraception Participant must have been vaccinated against N. men, S. pneumo, and H. influ at least 14 days prior to study drug initiation or received antibiotics for 14 days after the vaccinations  Prior eculizumab treatment Presence or suspicion of active bacterial infection at baseline Participation in another concurrent clinical study within at least 30 days prior to screening History of meningococcal/pneumococcal/gonococcal disease Pregnant, breast feeding, or intending to conceive during the study including the safety follow-up visits Any other condition that could increase the participant's risk or confound the outcome of the study
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Hemoglobinopathies Thalassemia Major or Sickle Cell Disease or Sickle/Beta Thalassemia patients Regularly transfused (hemoglobin ≥ 9.5 gr/dl) or not transfused, under or not iron chelation regimen With positivity to HCV-RNA and chronic liver disease with or without cirrhosis, naïve or non-responder or relapser after interferon mono-therapy  Thalassemia Major or Sickle Cell Disease or Sickle/Beta Thalassemia patients with not compensated liver failure or heart failure Low white blood cells (neutrophils < 1.500/mmc and/or white blood cells < 3.000/mmc) Low platelets count (< 100.000/mmc) Significant positivity to Coombs test with clinical and serologic evidence of immune hemolytic anemia, severe endocrinopathy, detection of high titre autoantibodies, co-infection with HBV (HbsAg positive)
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hypotension Shock Patients with controlled mechanical ventilation, equipped with an indwelling radial artery catheter and for whom the decision to give fluids will be taken because the presence of one or more clinical signs of acute circulatory failure systolic blood pressure <90 mmHg (or a decrease >50 mmHg in previously hypertensive patients) the need of vasopressor drugs oliguria (urine output <0.5 ml/kg/min for at least 2 h) tachycardia delayed capillary refilling the presence of skin mottling  Contraindication for the volume administration: evidence of fluid overload and/or of hydrostatic pulmonary edema Patients with instable cardiac rhythm
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 19.0-70.0,  Acute Renal Failure Infection Age 19 to 70 years Suspected or proven infection requiring parenteral antifungal therapy Continuous venovenous hemofiltration because of an acute renal failure  Known history of hypersensitivity to echinocandins An expected survival of less than three days Known alcohol dependency, epilepsy, pregnancy or liver failure Neutropenic patients
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Meningitis Septicemia Participant is willing and able to give informed consent for participation after the nature of the study has been explained Male or Female, aged 18 years inclusive In good health as determined by Medical history History-directed physical examination Clinical judgment of the investigator Female participants of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter Able (in the Investigator's opinion) and willing to comply with all study requirements Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study  Are unwilling or unable to give written informed consent to participate in the study Have previously received any meningococcal vaccine (this will be confirmed with the participant's general practitioner after enrolment) Have previously been diagnosed with laboratory confirmed meningococcal disease Have a history of any anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component Have a known or suspected autoimmune disease or impairment /alteration of immune function resulting from (for example) Receipt of any immunosuppressive therapy Congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months or long-term systemic corticosteroid therapy* (*prednisolone or equivalent for more than two consecutive weeks within the past 3 months) Have a suspected or known HIV infection or HIV related disease Have received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 3 months Have a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Thrombotic Thrombocytopenic Purpura Microangiopathic hemolytic anemia (< 12 g/dL) with thrombocytopenia <50 G/L, and mild or no renal failure (Serum creatinine < 150 µmol/L) negative Beta HCG and ongoing contraception during treatment and during the 24 months following the last infusion of rituximab refractory TTP (after 4 days of standard treatment) > 18 year old and signed written informed consent  Hemolytic uremic syndrome (platelet count ³ 50 G/L and serum creatinine ³ 150 micromol/L) TTP associated with another condition (HIV infection, cancer and/or chemotherapy, transplantation) previous treatment with vincristine or cyclophosphamide or other immunomodulatory drugs (except steroids), within 2 months before  ongoing or planned pregnancy, lactation
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Sepsis Patient with a septic shock diagnosed by the medical staff team Patient mechanically ventilated and treated by high doses of catecholamines after adequate fluid administration (≥ 1.0 mg/h of norepinephrine or epinephrine) for ≥ 120 minutes and < 24h  Age (years) < 18 or > 85 Weight >120 kg Thrombocytopenia 50< G/l or Neutrophils <0.5 Giga/l Contra indication to heparin anticoagulation Patient requiring catecholamines (epinephrine ≥ 1 mg/h or norepinephrine ≥ 1 mg/h) for >24h Patient admitted to the ICU ≥ 7 days before the criteria Comorbid conditions with an expected survival < 6 months (<28 days) in another study interfering with the goals of the current investigation Pregnancy Immune compromised patients (e.g. being treated for cancer, treated by immunosuppressors or steroids, AIDS)
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Anemia, Aplastic Anemia, Hypoplastic Thrombocytopenia Diagnosis of aplastic anemia, with refractory thrombocytopenia following at least one treatment course of horse or rabbit ATG/cyclosporine. 2. Platelet count less than or equal to 30,000/microL 3. Age greater than or equal to 12 years old  Diagnosis of Fanconi anemia 2. Infection not adequately responding to appropriate therapy 3. Patients with a PNH clone size in neutrophils of greater than or equal to 50% 4. HIV positivity 5. Creatinine > 2.5 6. Bilirubin > 2.0 7. SGOT or SGPT > 5 times the upper limit of normal 8. Hypersensitivity to eltrombopag or its components 9. Female subjects who are nursing or pregnant or are unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential 10. History of malignancy other than localized tumors diagnosed more than one year previously and treated surgically with curative intent (for instance squamous cell or other skin cancers, stage 1 breast cancer, cervical carcinoma in situ, etc) 11. Unable to understand the investigational nature of the study or give informed consent 12. History of congestive heart failure arrhythmia requiring chronic treatment, arterial or venous thrombosis (not excluding line thrombosis) within the last 1 year, or myocardial infarction within 3 months before enrollment 13. ECOG Performance Status of 3 or greater 14. Treatment with horse or rabbit ATG or Campath within 6 months of study entry. Concurrent stable treatment with cyclosporine or G-CSF is permitted